Short Interest in Hims & Hers Health, Inc. (NYSE:HIMS) Rises By 5.3%

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 18,390,000 shares, a growth of 5.3% from the April 15th total of 17,470,000 shares. Based on an average trading volume of 6,060,000 shares, the short-interest ratio is presently 3.0 days. Approximately 13.2% of the shares of the stock are short sold.

Hims & Hers Health Price Performance

HIMS traded up $0.54 on Friday, hitting $14.58. The company had a trading volume of 5,433,888 shares, compared to its average volume of 5,281,174. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16. The stock has a fifty day simple moving average of $13.92 and a 200-day simple moving average of $10.74. The firm has a market capitalization of $3.13 billion, a P/E ratio of -1,457.50 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analysts' expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm's revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS. Equities research analysts expect that Hims & Hers Health will post 0.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. SVB Leerink initiated coverage on Hims & Hers Health in a research note on Monday, February 26th. They issued a "market perform" rating and a $10.00 target price for the company. TheStreet raised Hims & Hers Health from a "d" rating to a "c" rating in a research note on Monday, March 4th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a "hold" rating in a report on Tuesday, May 7th. Finally, Seaport Res Ptn reissued a "buy" rating on shares of Hims & Hers Health in a report on Friday, April 26th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $15.08.

Insider Buying and Selling

In other news, insider Irene Becklund sold 2,747 shares of the company's stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $12.08, for a total value of $33,183.76. Following the completion of the transaction, the insider now directly owns 5,494 shares in the company, valued at approximately $66,367.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Melissa Baird sold 11,751 shares of Hims & Hers Health stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $13.99, for a total value of $164,396.49. Following the transaction, the chief operating officer now owns 507,465 shares in the company, valued at approximately $7,099,435.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Irene Becklund sold 2,747 shares of the business's stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $12.08, for a total transaction of $33,183.76. Following the completion of the sale, the insider now directly owns 5,494 shares of the company's stock, valued at $66,367.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 588,695 shares of company stock worth $8,342,715. Corporate insiders own 31.63% of the company's stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Graham Capital Management L.P. boosted its stake in Hims & Hers Health by 39.4% during the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company's stock worth $2,141,000 after acquiring an additional 96,277 shares in the last quarter. Swiss National Bank grew its stake in shares of Hims & Hers Health by 9.2% in the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company's stock worth $1,945,000 after buying an additional 26,100 shares during the last quarter. Vanguard Group Inc. increased its position in Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock valued at $88,857,000 after buying an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp increased its position in Hims & Hers Health by 11.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company's stock valued at $3,551,000 after buying an additional 58,288 shares in the last quarter. Finally, Must Asset Management Inc. purchased a new position in Hims & Hers Health during the third quarter valued at $1,596,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.